MARKET

NLTX

NLTX

Neoleukin Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.10
-0.70
-6.48%
Closed 16:00 04/03 EDT
OPEN
10.73
PREV CLOSE
10.80
HIGH
11.05
LOW
9.60
VOLUME
311.73K
TURNOVER
--
52 WEEK HIGH
13.71
52 WEEK LOW
2.190
MARKET CAP
387.57M
P/E (TTM)
-3.9078
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average NLTX stock price target is 19.50 with a high estimate of 20.00 and a low estimate of 18.00.

EPS

NLTX News

More
  • Medicenna's Potential Best-In-Class IL-2 Superkine Program Making Progress
  • Seeking Alpha - Article · 3d ago
  • B of A Securities Initiates Coverage On Neoleukin Therapeutics with Buy Rating, Announces $18 Price Target
  • Benzinga · 03/16 11:12
  • Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/13 01:30
  • Neoleukin Therapeutics EPS beats by $0.07
  • seekingalpha · 03/13 01:19

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About NLTX

Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
More

Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to help you make informed decisions.